A pair of CDMOs are bringing in new CEOs.
Taking the helm at BioCina is Mark Womack. According to his LinkedIn profile, Womack has been in leadership positions at several contract manufacturers. His career spans more than 30 years, including roles such as CEO of the contract manufacturer KBI Biopharma and Selexis SA. Before that, he was CEO of Stelis Biopharma and chief business officer of Seattle-based manufacturer AGC Biologics.
Former BioCina CEO Ian Wisenberg will join the board of directors as executive chairman.
“I’m tremendously excited to lead the highly talented and deeply committed BioCina team and to build on all of the success they’ve achieved to date. Leveraging BioCina’s core strengths, we will become a preeminent Global Biologics CDMO through industry-leading quality, a client-centric approach and on-time delivery of client programs,” Womack announced in a release.
In 2021, BioCina finalized…
Click here to view original post
